Annotation
Kardiovize is a multidisciplinary epidemiological project focused on the prevention of cardiovascular and age-related diseases in the population of Brno. The project is based on a population cohort study – a randomly selected sample of people aged 25-64 years, stratified by age and sex, representing 1% of the adult population of Brno. This prospective study was designed to assess the prevalence of cardiovascular disease and its risk factors, but also to monitor long-term trends in the central European urban population living in the Czech Republic.
The first phase of the project, including recruitment and baseline examination of the Kardiovize cohort (Baseline), was conducted in 2013-2014. Several additional examinations were completed in 2015-2016.
The next phase of the project (Follow-up) focused on monitoring changes in cardiovascular parameters and cardiovascular risk factors in the Kardiovize cohort. Recruitment and examinations for this phase will take place between 2019 and 2022.
The Parental Study is a follow-up project focusing on the prevalence of cardiovascular disease and its risk factors in the elderly population. Individuals aged 65 years and older were invited to participate in this secondary cohort on the basis of relationship – they were parents of participants in the primary Kardiovize cohort. Recruitment and screening took place in 2018-2019.
Research Projects
- Prevalence of cardiovascular disease risk factors in the Brno population – pilot study KARDIOVIZE BRNO 2030 (Recruitment completed)
- Kardiovize Brno 2030: study of parents 65+ (Recruitment completed)
- Follow-up study of the Kardiovize Brno 2030 cohort (Recruitment completed)
- Comprehensive biomarkers of neurodegenerative diseases and cardiovascular risk factors in participants of the Kardiovize study (Recruitment is ongoing)
Basic Description of the Dataset
The primary cohort of Kardiovize was based on a randomized selection of a cohort of persons aged 25-64 years, stratified by age and sex, representing 1% of the adult population of Brno in that age group. The randomized selection of participants (January 2013 and April 2014) was carried out with the technical support of the General Health Insurance Company managing the register of insured persons of all health insurance companies operating in the Czech Republic. The eligibility criteria for participation included: age 25-64 years, permanent residence in Brno and registration with one of the five cooperating health insurance companies, covering 91.1% of the population in total – this criterion ensured the representativeness of the sample and the relevance of the data obtained for the objectives.
The baseline examination of participants included a comprehensive health interview (demographics, family, personal and pharmacological history, assessment of psychosocial and lifestyle factors), clinical and instrumental measurements, collection of biological material, subsequent laboratory analysis of blood and urine samples, and freezing and long-term preservation of biological samples (isolated DNA, blood plasma and blood serum) for later analysis.
BASELINE
- Sample size: 2 159 (M 978, F 1181)
- Age range: 25-64 years
- Average age: 47.4
- Data collection: 2013-2014 (Baseline), 2015-2016 (additional measures)
PARENTAL
- Sample size: 274 (M 96, F 178)
- Age range: 64-89 years
- Average age: 72.0
- Data collection: 2018-2019
FOLLOW-UP
- Sample size: 865 (M 417, F 448)
- Age range: 33-73 years
- Average age: 66.5
- Data collection 2019-2022
Funding Sources
- OP VaVpI (Registration number: CZ.1.05/1.1.00/02.0123)
- NPU (Registration number: LQ1605)
- IGA (Registration number: NT13434)
- ENOCH (Registration number: CZ.02.1.01/0.0/0.0/16_019/0000868)
- NPO (Registration number: LX22NPO5107)
Acknowledgement
The authors gratefully acknowledge the Kardiovize team for providing data, supporting and collaborating on this publication.
